泓博医药(301230.SZ)发布前三季度业绩，归母净利润3474.96万元，增长127.96%

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong business performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 514 million yuan, representing a year-on-year growth of 31.43% [1] - The net profit attributable to shareholders of the listed company was 34.75 million yuan, showing a year-on-year increase of 127.96% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 27.71 million yuan, reflecting a substantial year-on-year growth of 353.43% [1] - Basic earnings per share stood at 0.2489 yuan [1]